Inhibikase Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals

Company to host conference call and webcast on tuesday, may 17, 2022, at 8:00am et boston and atlanta , may 16, 2022 /prnewswire/ -- inhibikase therapeutics, inc. (nasdaq: ikt) (inhibikase or company), a clinical-stage pharmaceutical company developing therapeutics to modify the course of parkinson's disease and related disorders, today reported financial results for the first quarter ended march 31, 2022 and highlighted recent developments. "as we kicked off 2022, we have worked diligently to advance our clinical and preclinical programs as well as extend our thought leadership in parkinson's disease.

Boston and atlanta , march 31, 2022 /prnewswire/ -- inhibikase therapeutics, inc. (nasdaq: ikt) (inhibikase or company), a clinical-stage pharmaceutical company developing therapeutics to modify the course of parkinson's disease and related disorders, today reported financial results for the full year ended december 31, 2021 and highlighted recent developments. "2021 was an important year for inhibikase as we advanced our lead program ikt-148009 for parkinson's disease into the clinic, continued to develop our early-stage pipeline programs and strengthened our balance sheet to support our development efforts well into 2023," commented dr. milton h.

Boston and atlanta , march 23, 2022 /prnewswire/ -- inhibikase therapeutics, inc. (nasdaq: ikt) (inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of parkinson's disease and related disorders, today announced that dr. milton werner, ph.d., the company's president & chief executive officer will present in the maxim group 2022 virtual growth conference, being held from march 28 th through 30th.

Boston and atlanta, jan. 5, 2022 /prnewswire/ -- inhibikase therapeutics, inc. (nasdaq: ikt) (inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of parkinson's disease and related disorders, today highlighted recent developments and anticipated milestones for 2022. key business and clinical milestones expected in 2022: continue phase 1 dose escalation of ikt-148009 in older and elderly healthy volunteers: ikt-148009 continues to be evaluated at higher single doses in older and elderly healthy volunteers as part of the phase 1 study, which was initiated in february 2021.

Boston and atlanta, nov. 29, 2021 /prnewswire/ -- inhibikase therapeutics, inc. (nasdaq: ikt) ("inhibikase" or "company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of parkinson's disease and related disorders, today announced the publication of a paper describing the biochemical rationale and potential benefit of abelson tyrosine kinase (c-abl) inhibition as a potential disease-modifying therapy for parkinson's disease. the article, titled "parkinson's disease modification through abl kinase inhibition: an opportunity" was published online in the journal movement disorders on november 24, 2021 (doi:  10/1002/mds.28858).

Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q1 2022 Earnings Conference Call May 17, 2022 8:00 AM ET Company Participants Alex Lobo - Stern Investor Relations Milton Werner - Chief Executive Officer Joseph Frattaroli - Chief Financial Officer Conference Call Participants Operator Greetings, welcome to Inhibikase Therapeutics' First Quarter 2022 Financial Results Conference Call. At this time, all participants are in listen-only mode.

BOSTON and ATLANTA , May 10, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that Dr. Milton Werner, Ph.D., the Company's President & Chief Executive Officer will present at the upcoming H.C.

Inhibikase Therapeutics, Inc. (IKT) CEO Dr. Milton Werner on Q4 2021 Results - Earnings Call Transcript

BOSTON and ATLANTA, Mar. 25, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that it will report financial results for the full year ended December 31, 2021 on Thursday, March 31, 2022, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m.

BOSTON and ATLANTA, March 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that Dr. Milton Werner, Ph.D., President & Chief Executive Officer of Inhibikase, will give an oral presentation at the AD/PD™, Alzheimer's & Parkinson's Diseases Conference being held in Barcelona, Spain from March 15-20, 2022.

The stock price of Inhibikase Therapeutics Inc (NASDAQ: IKT) increased by over 10% pre-market today. This is why it happened.

ATLANTA, Oct. 19, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced dosing of the first Parkinson's patient in its Phase 1b clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson's disease. The Phase 1b extension study is a 3:1 randomized, placebo-controlled trial investigating the safety, tolerability and pharmacokinetics of IkT-148009.

The stock price of Inhibikase Therapeutics, Inc. (Nasdaq: IKT) increased over 5% pre-market today. This is why it happened.

ATLANTA, Oct. 4, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced interim three-month results from its ongoing chronic toxicology studies of oral IkT-148009 administered in rats and non-human primates (NHPs). The Company's ongoing toxicology studies of IkT-148009 are designed to meet the regulatory requirements for chronic dosing in humans, which include daily oral administration in rats for six months and in NHPs for nine months.

ATLANTA, Sept. 23, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that the Company has been awarded a $385,388 research grant from the U.S. National Institute of Neurological Disease and Stroke (NINDS), an Institute of the National Institutes of Health (NIH), to evaluate the therapeutic potential of IkT-148009, the Company's lead c-Abl inhibitor,  in a novel preclinical model for Multiple System Atrophy (MSA).